<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01981447</url>
  </required_header>
  <id_info>
    <org_study_id>09-00570-FB</org_study_id>
    <nct_id>NCT01981447</nct_id>
  </id_info>
  <brief_title>IV Lacosamide: The Safety of Intravenous Lacosamide</brief_title>
  <official_title>IV Lacosamide: The Safety of Intravenous Lacosamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Le Bonheur Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Le Bonheur Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of IV Lacosamide in children ages 4-35.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the safety of IV Lacosamide in children ages 4&#xD;
      years to 35 years, inclusive who are unable to take oral medications or require parenteral&#xD;
      administration of IV Lacosamide Occasionally, patients over the age of 20 are seen at&#xD;
      LeBonheur Children's Hospital due to the complexity of their condition, or due to a long&#xD;
      relationship with their physician. These are exceptions which are reviewed on a case by case&#xD;
      basis and are approved by the hospital administrator for admissions and outpatient testing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events (TEAEs), reported or observed.</measure>
    <time_frame>2 years</time_frame>
    <description>Bradycardia, hypotension, fatigue, nausea, somnolence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure post-infusion lacosamide plasma concentrations</measure>
    <time_frame>2 years</time_frame>
    <description>Serum lacosamide level drawn from the arm opposite intravenous infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure changes in EKG, PR interval</measure>
    <time_frame>2 years</time_frame>
    <description>PR interval changes measured in seconds</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV Lacosamide administered (intravenously) over 30 minutes: 0.7mg/kg, 1.4 mg/kg, 2.1 mg/ kg and 2.9 mg/kg over 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV Lacosamide to be administered (intravenously) over 15 minutes: 0.7mg/kg, 1.4 mg/kg, 2.1mg/kg, 2,4 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Lacosamide</intervention_name>
    <description>Lacosamide administered intravenously over 15 or 30 minutes, depending on study arm, to patients with epilepsy.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient or LAR must sign informed consent&#xD;
&#xD;
          -  Diagnosis of partial onset currently uncontrolled&#xD;
&#xD;
          -  Patient must have received anti-epileptic drug therapy prior to initiation&#xD;
&#xD;
          -  Patient must have a medical condition in which parental administration is desireable&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Ages 4-35&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has participated in a study involving IV Lacosamide&#xD;
&#xD;
          -  Patient has had an episode of status epilepticus in the last 3 months&#xD;
&#xD;
          -  Drug history to lacosamide pregnant or lactating&#xD;
&#xD;
          -  If of child bearing age, must have pregnancy test&#xD;
&#xD;
          -  Patient has participated in an experimental drug study in last 30 days&#xD;
&#xD;
          -  Patients with significant active hepatic or renal disease.&#xD;
&#xD;
          -  Patients with known cardiac disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James W Wheless, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lebonheur Children's Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lebonheur Children's Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 13, 2013</study_first_submitted>
  <study_first_submitted_qc>November 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2013</study_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Le Bonheur Children's Hospital</investigator_affiliation>
    <investigator_full_name>James W. Wheless</investigator_full_name>
    <investigator_title>Principal Investigaor, Neurolgy Division Chief</investigator_title>
  </responsible_party>
  <keyword>epilepsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacosamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

